

# Mi Ran Yun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3543800/publications.pdf>

Version: 2024-02-01

13  
papers

334  
citations

1040056

9  
h-index

1199594

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

517  
citing authors

#	ARTICLE	IF	CITATIONS
1	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2575-2587.	7.0	71
2	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4397-4409.	7.0	49
3	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018, 78, 3350-3362.	0.9	42
4	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10581.	6.9	40
5	Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells. <i>Cellular Signalling</i> , 2014, 26, 705-715.	3.6	36
6	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018, 124, 168-178.	2.0	23
7	Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK Positive Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 491-500.	1.1	21
8	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. <i>Nature Biomedical Engineering</i> , 2018, 2, 239-253.	22.5	18
9	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 153, 179-189.	2.8	16
10	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791.	3.2	10
11	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. <i>Yonsei Medical Journal</i> , 2022, 63, 42.	2.2	7
12	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. <i>Cancer Research</i> , 2022, 82, LB515A-LB515A.	0.9	1
13	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. <i>Cancer Research</i> , 2022, 82, LB544-LB544.	0.9	0